Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Trastuzumab has an established role for the treatment of HER2-positive early-stage breast cancer. The authors of this review discuss the toxicity associated with trastuzumab and the issues associated with determining its optimum timing and schedule, and assert why this agent should be the standard of care in the adjuvant setting.
Trastuzumab has...
Alternative Titles
Full title
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2039357125
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2039357125
Other Identifiers
ISSN
1743-4254,1759-4774
E-ISSN
1743-4262,1759-4782
DOI
10.1038/ncponc1298
